Trial Profile
LUX-Lung 7: A Randomised, Open-label Phase IIb Trial of Afatinib Versus Gefitinib as First-line Treatment of Patients With EGFR Mutation Positive Advanced Adenocarcinoma of the Lung
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Jan 2022
Price :
$35
*
At a glance
- Drugs Afatinib (Primary) ; Gefitinib
- Indications Adenocarcinoma; Lung cancer; Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms LUX-Lung 7
- Sponsors Boehringer Ingelheim
- 10 Sep 2019 Results accessing impact of afatinib on central nervous system (CNS) progression or metastatic spread in LUX-Lung 3, 6, and 7 studies were presented at the 20th World Conference on Lung Cancer.
- 01 Jun 2019 Results of post hoc analysis of tolerability-guided dose adjustment for afatinib published in the Journal of Cancer Research and Clinical Oncology
- 23 Apr 2019 Status changed from active, no longer recruiting to completed.